Penumbra, Inc. (PEN) on Decifer

Decifer ranks PEN number 178 of 270 tracked names on durable business quality.

Why it ranks here

• It earns solid returns on the money it puts to work, around 10% and those returns have been improving and it turns most of its profit into real cash.
• Revenue is growing about 17% a year, profits grew 1,169% over the past year, and growth is speeding up, not slowing down.
• It keeps a high share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power, with profitability widening as it grows.
• and has the balance sheet to fund its growth.
• We do not have a clean read on how it is run yet.
• Revenue up 17% with profits up 1169% is impressive, but momentum of 7 out of 35, no clean read on management, and no funded role hold it back.

The current read

The evidence on PEN lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• Robotic & Minimally-Invasive Intervention: Clinical and economic evidence favoring minimally invasive robotic and thrombectomy procedures is shifting procedure volumes and capital equipment budgets toward advanced interventional platforms.

Read the full PEN research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.